Transformative Federal Health Laws and Their Implications for 2026
The year 2025 witnessed pivotal transformations in federal health laws, setting the stage for ongoing developments in 2026. The Omicron Bipartisan Budget Balancing Act (OBBBA), enacted mid-2025, significantly impacted Medicaid, Medicare, and the Affordable Care Act (ACA). Designed to strengthen health coverage and fortify program integrity, these changes revise eligibility and verification standards for ACA marketplace enrollment. The cessation of enhanced ACA premium tax credits may increase costs for enrollees unless additional legislative measures are introduced.
The Inflation Reduction Act of 2022 initiated a groundbreaking drug pricing negotiation program for Medicare, launching in January 2026. This program caps the costs for ten Medicare Part D drugs, adjusting prices only for inflation or further negotiation. The program will expand its scope, including fifteen additional drugs annually in 2027 and 2028, and twenty more each following year.
In 2025, digital health advanced rapidly, urging updates in legal oversight for AI and telemedicine. While proposals to expand regulations over electronic health platforms emerged, concerns linger over technology outpacing regulatory safeguards. Meanwhile, heightened data privacy focus led to updates in HIPAA's Notice of Privacy Practices, mandating enhancements by February 2026 to encompass substance use disorder information.
The Federal Trade Commission (FTC) held firm in its intensive scrutiny of healthcare mergers and acquisitions despite administrative changes. Initiating significant investigations into pharmacy benefits managers in 2025, the agency advised healthcare systems to reassess non-compete agreements. As these agreements potentially limit employment opportunities and affect patient care accessibility, they face growing scrutiny at both federal and state levels.
The government's commitment to combating healthcare fraud persisted with the launch of the "National Health Care Fraud Takedown" in 2025. This extensive operation, involving federal and state entities, targeted fraudulent billing and drug diversion initiatives, leading to criminal charges against 324 individuals, including medical professionals. Ongoing investigations are anticipated to extend into 2026.
Although President Trump's Great Healthcare Plan was not introduced in 2025, its unveiling in early 2026 brings proposals to reduce drug prices, lower insurance premiums, and enhance insurer accountability. The plan also emphasizes transparency in pricing from healthcare providers accepting Medicare or Medicaid. These proposals align with the Centers for Medicare & Medicaid Services (CMS) efforts to streamline insurance pricing, as congressional and executive discussions with industry leaders continue.
As we move into 2026, the federal health law landscape remains dynamic, with healthcare providers, insurers, and associated stakeholders preparing to navigate ongoing regulatory changes and intense scrutiny.